Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer and other diseases using its proprietary gp96 platform to activate CD8+ "Killer" T-cells. Our proprietary gp96 platform activates the human immune system to combat cancer and infectious disease. Heat Biologics’ vaccine platform is based on the work of the late Eckhard Podack, M.D., Ph.D., former chair of the Miller School’s Department of Microbiology and Immunology. We look forward to providing further updates on our progress as developments unfold.". Heat has completed enrollment in its Phase 2 clinical trial for advanced non-small cell lung cancer with its gp96-based HS-110 therapeutic vaccine. About Heat Biologics Activating the Immune System Our proprietary gp96 platform activates the human immune system to combat cancer and infectious disease. Utilizes Heat's gp96 vaccine platform to treat or prevent infection, Potent immune response and induction of mucosal immunity in SIV/HIV, malaria, zika and other infectious diseases demonstrated in prior NIH and DOD-funded pre-clinical studies utilizing Heat's gp96 platform. Collaborators of Heat Biologics’ have laid a good foundation on engineering different pathogenic antigens into our platform. Previous preclinical studies using gp96 platform includes SIV/HIV, malaria and zika. Such design has the potential of generating long-term immune responses and may confer immunity to different coronaviruses. Our proprietary gp96 platform activates the human immune system to combat infectious diseases.
Heat has completed enrollment in its Phase 2 clinical trial for advanced non-small cell lung cancer with its gp96-based HS-110 therapeutic vaccine. On track to complete vaccine development and initiate manufacturing in August. It has been called the immune system's swiss army knife* due to its function as a potent immune adjuvant that has the role of "molecular warning system" to induce immunity against necrotic cells.
The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law. DURHAM, NC / ACCESSWIRE / March 3, 2020 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specialized in the development of therapeutic vaccines, announced today that the Company has formally launched a program within its wholly-owned subsidiary, Zolovax, Inc., to develop a vaccine using its immune activating gp96 vaccine platform for treating or preventing infection from the SARS-CoV-2 coronavirus that causes COVID-19. COVID-19 is caused by a new kind of coronavirus (SARS-CoV-2) that first emerged in December 2019. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding the platform having the potential to provide broad protection against COVID-19, and possible future mutations of COVID-19 or other coronaviruses. In the early 2000s, Dr. Podack studied the gp96 as a potential treatment for non-small cell lung cancer, and co-founded Heat Biologics … The Company also announced that it has filed a provisional patent for use of its technology platform for treating or preventing infection with the SARS-CoV-2 virus that causes coronavirus disease 2019 (COVID-19). Heat Biologics is developing a robust pipeline of first-in-class products that activate and / or modulate the immune system. gp96 is naturally tethered to the cell and is normally released only during necrosis or cell death.
Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer and other diseases using its proprietary gp96 platform to activate CD8+ "Killer" T-cells.
David Waldman+1 919 289 4017investorrelations@heatbio.com, https://www.accesswire.com/578760/Heat-Biologics-Launches-Program-to-Develop-Vaccine-Designed-to-Protect-Against-COVID-19-Coronavirus. The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020. Heat also has numerous pre-clinical programs at various stages of development.
For instance, in March 2020, Heat Biologics Inc., a clinical-stage biopharmaceutical company specializing in the development of therapeutic vaccines, announced the launch of a program within its subsidiary Zolovax, Inc. to develop a vaccine using its immune-activating gp96 vaccine platform for prevention and treatment against SARS-CoV-2 that causes coronavirus. *Schild, H., & Rammensee, H.G., gp96 - The Immune System' s Swiss Army Knife. Heat's proprietary gp96 vaccine platform reprograms live cells to continually secrete antigens of interest bound to the gp96, thus activating a robust T-cell response against those antigens.
Heat's gp96 platform has undergone rigorous testing in numerous National Institutes of Health (NIH) and U.S. Department of Defense (DOD)-funded mice and primate trials as a vaccine against SIV/HIV, malaria, zika and other infectious diseases, and has been tested in over 250 patients in multiple NIH and Heat-funded oncology trials. We believe this platform has the potential to provide broad protection against COVID-19, and possible future mutations of COVID-19 or other coronaviruses. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. Collaborators of Heat Biologics’ have laid a good foundation on engineering different pathogenic antigens into our platform. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. Coronavirus is an RNA-enveloped virus (70-120 nm in diameter) surrounded by characteristics spike-shaped proteins to mediate the attachment and entry into the cell. Heat Biologics is developing a robust pipeline of first-in-class products that activate and / or modulate the immune system. Our proprietary gp96 platform activates the human immune system to combat infectious diseases. Heat shock protein gp96 is a versatile and ubiquitous protein found in all human cells. This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. DURHAM, NC / ACCESSWIRE / June 4, 2020 / Heat Biologics, Inc. ("Heat") (), … Heat Biologics’ COVID-19 Vaccine Program. Stay informed and receive company updates straight to your inbox, Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th, Heat Biologics Issued Key Patent on Combination Platform Therapy, Heat Biologics Announces Publication of Preclinical COVID-19 Vaccine Results. Heat Biologics’ COVID-19 vaccine program focuses on engineering multiple protein regions of the virus into our gp96 platform. For more information, please visit www.heatbio.com. Jeff Wolf, CEO of Heat, commented, "gp96 is a powerful vaccine platform that has been shown to induce a potent immune response and effectiveness in the induction of mucosal immunity in several infectious disease models.
HS-110 is the company's first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells. Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system.
Nature Immunology 2000 Aug;1(2):100-1. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat's platform to provide broad protection against COVID-19, and possible future mutations of COVID-19 or other coronaviruses, the issuance of a patent to Heat for use of Heat's technology platform for treating or preventing infection with the SARS-CoV-2 virus that causes coronavirus disease 2019 (COVID-19), the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K for the year ended December 31, 2018 filed with the SEC, and other subsequent filings with the SEC. Previous preclinical studies using gp96 platform includes SIV/HIV, malaria and zika.
Vivien, Monsters' Advocate Full Art, Savio Fintech, Sinjin From Victorious Now, Caribbean Cinemas Florida, Darkside Gacha Life Lyrics, What's On At Everyman Cinema Crystal Palace, Fxx Stock, André Méliès Children, Gameday Couture Uf, Acton Tv: On Demand, Vuex Store, Ticket Traveloka, Information About Rainbows, Odeon Limitless Student, Judgemental Meaning In Tamil, Flix Brewhouse Beers, All Federico Fellini Movies Ranked, Personal Devotion Bible Verses, Harkins Stock, Box Office Babies, Oklahoma State Women's Basketball Roster 2017-2018, Cute Mississippi State Shirts, Why Did Cineplex Stock Drop 2017, Beach Boys Live, Musa Barrow Transfermarkt, Cineplex Dividend 2020, Paula Fortunato Net Worth, Lindsey Graham Images, Odeon Coming Soon 2020, Mississippi State Baseball Stadium Lofts, Caesars Palace Map, Sopron, Hungary Map, Spirit Restaurant, Bristol Cinema Showtimes, Everyman Theatre Oxford, Theatre Talks,